Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pravastatin sodium, quantity: 10 mg - tablet - excipient ingredients: magnesium stearate; dibasic sodium phosphate; lactose monohydrate; croscarmellose sodium; colloidal anhydrous silica; microcrystalline cellulose; sodium lauryl sulfate; povidone; iron oxide red - as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. patients with previous myocardial infarction including those who have normal (4.0 to 5.5 mmol/l) serum cholesterol levels. patients with unstable angina pectoris (see clinical trials). as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trials).

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - pravastatin sodium, quantity: 40 mg - tablet - excipient ingredients: lactose monohydrate; microcrystalline cellulose; iron oxide red; povidone; sodium lauryl sulfate; croscarmellose sodium; colloidal anhydrous silica; dibasic sodium phosphate; magnesium stearate - as an adjunct to diet for the treatment of hypercholesterolaemia. prior to initiating therapy with pravastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. patients with previous myocardial infarction including those who have normal (4.0 to 5.5 mmol/l) serum cholesterol levels. patients with unstable angina pectoris (see clinical trials). as an adjunct to diet and lifestyle modification for the treatment of heterozygous familial hypercholesterolaemia in children and adolescent patients aged 8 years and older (see clinical trials).

USA - engelsk - NLM (National Library of Medicine)

b. braun medical inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium cation 0.9 g in 100 ml - 0.9% sodium chloride irrigation usp is indicated for all general irrigation, washing, rinsing and dilution purposes which permit use of a sterile, nonpyrogenic electrolyte solution. 0.9% sodium chloride irrigation usp is not for injection by usual parenteral routes. an electrolyte solution should not be used for irrigation during electrosurgical procedures.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - sitagliptin phosphate monohydrate, quantity: 64.25 mg; metformin hydrochloride, quantity: 1000 mg - tablet - excipient ingredients: microcrystalline cellulose; sodium lauryl sulfate; sodium stearylfumarate; povidone; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - janumet (sitagliptin phosphate monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.,[see sections 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - metformin hydrochloride, quantity: 850 mg; sitagliptin phosphate monohydrate, quantity: 64.25 mg - tablet - excipient ingredients: microcrystalline cellulose; sodium stearylfumarate; povidone; sodium lauryl sulfate; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - janumet (sitagliptin phosphate monohydrate and metformin hydrochloride) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.,[see sections 5.1 pharmacodynamic properties, clinical trials and 4.2 dose and method of administration].

USA - engelsk - NLM (National Library of Medicine)

b. braun medical inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium chloride 9 mg in 1 ml - this intravenous solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. this product is designed for use as a diluent and delivery system for intermittent intravenous administration of compatible drug additives. consult prescribing information for indications and usage  of drug additives to be administered in this manner. this solution is contraindicated where the administration of sodium or chloride could be clinically detrimental.

USA - engelsk - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - sodium phenylbutyrate (unii: nt6k61736t) (phenylbutyric acid - unii:7wy7ybi87e) - sodium phenylbutyrate tablets are indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (cps), ornithine transcarbamylase (otc), or argininosuccinic acid synthetase (as). it is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. it is important that the diagnosis be made early and treatment initiated immediately to improve survival. any episode of acute hyperammonemia should be treated as a life-threatening emergency. sodium phenylbutyrate tablets must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation (see nutritional supplementation subsection of the dosage and administration section). previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. however, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. most deaths have occurred during an episode of acute hyperammonemic encephalopathy. patients with neonatal-onset disease have a high incidence of mental retardation. those who had iq tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients tested). retardation was severe in the majority of the retarded patients. in patients diagnosed during gestation and treated prior to any episode of hyperammonemic encephalopathy, survival is 100%, but even in these patients, most subsequently demonstrate cognitive impairment or other neurologic deficits. in late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recover from hyperammonemic encephalopathy and are then treated chronically with sodium phenylbutyrate and dietary protein restriction, the survival rate is 98%. the two deaths in this group of patients occurred during episodes of hyperammonemic encephalopathy. however, compliance with the therapeutic regimen has not been adequately documented to allow evaluation of the potential for sodium phenylbutyrate tablets and dietary protein restriction to prevent mental deterioration and recurrence of hyperammonemic encephalopathy if carefully adhered to. the majority of these patients tested (30/46 or 65%) have iq’s in the average to low average/borderline mentally retarded range. reversal of preexisting neurologic impairment is not likely to occur with treatment and neurologic deterioration may continue in some patients. even on therapy, acute hyperammonemic encephalopathy recurred in the majority of patients for whom the drug is indicated. sodium phenylbutyrate tablets may be required lifelong unless orthotopic liver transplantation is elected. (see clinical pharmacology, pharmacodynamics subsection for the biochemical effects of sodium phenylbutyrate tablets). sodium phenylbutyrate tablets should not be used to manage acute hyperammonemia, which is a medical emergency.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - sodium cellulose phosphate 100% - powder for oral solution - 100 % - active: sodium cellulose phosphate 100%

Israel - engelsk - Ministry of Health

teva medical ltd - sodium chloride - solution for injection - sodium chloride 0.9 g / 100 ml - sodium chloride - sodium chloride - a source of water and electrolytes. also indicated for use as priming solutions in hemodialysis procedures.

Israel - engelsk - Ministry of Health

isorad ltd, israel - iodine sodium - capsules - iodine sodium 37 mbq - sodium iodide (131i) - sodium iodide (131i) - treatment of graves disease, toxic multinodular goite or autonomous nodules.treatment of papillary and follicular thyroid carcinoma including metastatic disease. sodium iodide (i-131) therapy is often combined with surgical intervention and with antithyroid medications.